treatment | Page 50 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

treatment

Ravulizumab-cwvz

Ravulizumab-cwvz (Ultomiris®) is a drug approved by the U.S. Food and Drug Administration (FDA) in 2018 to treat PNH. ULTOMIRIS® is a long-acting C5 inhibitor that works by inhibiting the C5 protein in the terminal complement cascade.  ULTOMIRIS® is a prescription medicine called a

Kat Edmonds knows patients, but more importantly, she coaches them on how to make the best decisions for their own lives. Find out more here:

Kat hears patients ask: "I have this bone marrow failure problem ... how is this going to affect me and loved ones? What does this mean for my life?" Discover how Kat helps walk patients through diagnosis, treatment, and survivorship.